BRPI0812359A2 - Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo - Google Patents

Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo

Info

Publication number
BRPI0812359A2
BRPI0812359A2 BRPI0812359-4A2A BRPI0812359A BRPI0812359A2 BR PI0812359 A2 BRPI0812359 A2 BR PI0812359A2 BR PI0812359 A BRPI0812359 A BR PI0812359A BR PI0812359 A2 BRPI0812359 A2 BR PI0812359A2
Authority
BR
Brazil
Prior art keywords
tetrahydroisoquinolin
ona
derivative
salt
ona derivative
Prior art date
Application number
BRPI0812359-4A2A
Other languages
English (en)
Inventor
Hiroyuki Hisamichi
Itsuro Shimara
Tsukasa Ishihara
Tomofumi Takuwa
Takafumi Shimizu
Noriko Ishikawa
Kyoichi Maeno
Norio Seki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40075016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812359(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI0812359A2 publication Critical patent/BRPI0812359A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BRPI0812359-4A2A 2007-05-28 2008-05-26 Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo BRPI0812359A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007140097 2007-05-28
PCT/JP2008/059621 WO2008146774A1 (ja) 2007-05-28 2008-05-26 テトラヒドロイソキノリン-1-オン誘導体またはその塩

Publications (1)

Publication Number Publication Date
BRPI0812359A2 true BRPI0812359A2 (pt) 2015-01-27

Family

ID=40075016

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812359-4A2A BRPI0812359A2 (pt) 2007-05-28 2008-05-26 Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo

Country Status (23)

Country Link
US (5) US8486970B2 (pt)
EP (1) EP2149561B1 (pt)
JP (1) JP5336359B2 (pt)
KR (3) KR101830566B1 (pt)
CN (1) CN101668747B (pt)
AU (1) AU2008255815B2 (pt)
BR (1) BRPI0812359A2 (pt)
CA (1) CA2688326C (pt)
CY (1) CY1117004T1 (pt)
DK (1) DK2149561T3 (pt)
ES (1) ES2558677T3 (pt)
HR (1) HRP20151336T1 (pt)
HU (1) HUE026316T2 (pt)
IL (1) IL202301A (pt)
MX (1) MX2009012779A (pt)
PL (1) PL2149561T3 (pt)
PT (1) PT2149561E (pt)
RS (1) RS54429B1 (pt)
RU (1) RU2479578C2 (pt)
SI (1) SI2149561T1 (pt)
TW (1) TWI425945B (pt)
WO (1) WO2008146774A1 (pt)
ZA (1) ZA200908220B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
EP3180465B1 (en) * 2014-09-16 2020-04-08 SRI International Libraries of non-natural, dihydroisoquinolinone-based polymers for high-throughput drug screening through fiber-optic array scanning technology
MX2018009870A (es) * 2016-02-15 2018-11-29 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Inhibidores de taf1 para la terapia del cancer.
US10875834B2 (en) 2016-07-22 2020-12-29 Virginia Commonwealth University Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives
US11311528B2 (en) 2018-03-20 2022-04-26 Merck Sharp & Dohme Corp. Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors
CN110563687B (zh) * 2019-07-23 2022-09-30 上海合全医药有限公司 一种4-(氨基甲基)色烷-3-醇的制备方法
EP4074314A1 (en) * 2021-04-15 2022-10-19 Valdospan GmbH Isoquinoline derivatives for use as antiviral and antitumour agents
JP2024515336A (ja) 2021-04-15 2024-04-08 アールディーピー ファーマ アーゲー 抗ウイルス剤及び抗腫瘍剤として使用するためのイソキノリン誘導体
CN113603625B (zh) * 2021-08-12 2023-03-10 南京卓康医药科技有限公司 一种酮咯酸中间体的合成方法
EP4605376A1 (en) 2022-10-17 2025-08-27 RDP Pharma AG Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
WO2000050406A1 (en) 1999-02-22 2000-08-31 Lion Bioscience Ag Isoquinoline derivatives and isoquinoline combinatorial libraries
ATE305302T1 (de) * 1999-12-28 2005-10-15 Eisai Co Ltd Heterozyklische verbindungen mit sulfonamid- gruppen
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AR035513A1 (es) * 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
DE10146867A1 (de) * 2001-09-24 2003-04-24 Bayer Ag Tetrahydroisochinoline
AU2003249713A1 (en) 2002-07-03 2004-01-23 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
EP1613597B1 (en) * 2003-03-07 2007-11-07 Eli Lilly and Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
CN101921279A (zh) * 2003-10-01 2010-12-22 阿得罗公司 螺环杂环衍生物及其应用方法
ES2257168B1 (es) * 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8163744B2 (en) 2005-03-18 2012-04-24 Nexuspharma, Inc. Tetrahydro-isoquinolin-1-ones for the treatment of cancer
US8101580B2 (en) 2005-04-21 2012-01-24 Astellas Pharma Inc. Therapeutic agent for irritable bowel syndrome
RU2302417C1 (ru) * 2006-03-14 2007-07-10 Иващенко Андрей Александрович 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
WO2008034039A2 (en) * 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
US8586619B2 (en) * 2007-03-12 2013-11-19 Vm Therapeutics Llc Agents of calcium ion channel modulators
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8263607B2 (en) * 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
CA2688326A1 (en) 2008-12-04
CY1117004T1 (el) 2017-04-05
HUE026316T2 (en) 2016-06-28
US20170189390A1 (en) 2017-07-06
HRP20151336T1 (hr) 2016-01-15
KR101682638B1 (ko) 2016-12-05
KR20150090262A (ko) 2015-08-05
JP5336359B2 (ja) 2013-11-06
RS54429B1 (sr) 2016-04-28
US8486970B2 (en) 2013-07-16
EP2149561A1 (en) 2010-02-03
EP2149561B1 (en) 2015-09-09
CN101668747A (zh) 2010-03-10
US9526719B2 (en) 2016-12-27
TW200911251A (en) 2009-03-16
PT2149561E (pt) 2016-01-07
RU2479578C2 (ru) 2013-04-20
US20140058100A1 (en) 2014-02-27
MX2009012779A (es) 2010-02-17
AU2008255815A1 (en) 2008-12-04
JPWO2008146774A1 (ja) 2010-08-19
PL2149561T3 (pl) 2016-05-31
US10016410B2 (en) 2018-07-10
AU2008255815B2 (en) 2012-02-02
KR20100020982A (ko) 2010-02-23
EP2149561A4 (en) 2011-09-07
WO2008146774A1 (ja) 2008-12-04
ZA200908220B (en) 2011-02-23
IL202301A (en) 2017-07-31
US20190000832A1 (en) 2019-01-03
US10532048B2 (en) 2020-01-14
CN101668747B (zh) 2012-02-01
RU2009148507A (ru) 2011-07-10
DK2149561T3 (en) 2015-12-21
IL202301A0 (en) 2010-06-30
US20150359787A1 (en) 2015-12-17
CA2688326C (en) 2016-07-05
US9150541B2 (en) 2015-10-06
US20100227866A1 (en) 2010-09-09
ES2558677T3 (es) 2016-02-08
TWI425945B (zh) 2014-02-11
KR101830566B1 (ko) 2018-02-20
SI2149561T1 (sl) 2016-02-29
KR20160139067A (ko) 2016-12-06
KR101580298B1 (ko) 2016-01-08

Similar Documents

Publication Publication Date Title
FR24C1047I2 (fr) Derive de 4-pyrimidinesulfamide
BRPI0818201A2 (pt) Composto de azolcarboxamida ou sal do mesmo
EP2226315A4 (en) 2-aminoquinazoline DERIVATIVE
BRPI0807004A2 (pt) Sal
BRPI0816278A2 (pt) forma sal
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0814307A2 (pt) Sistema de tratamento presbiópico
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0816461A2 (pt) Derivados fungicidas de 2-alquiltio-2-quinolonolóxi-acetamida
BRPI0815935A2 (pt) sensor de posição
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
EP2072519A4 (en) DIARYLKETIMINDERIVAT
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0720220A2 (pt) Derivados de quinolinas antibacterianos
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0812359A2 (pt) Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0819415A2 (pt) Sensor de posição
BRPI0914121A2 (pt) derivado de triazol ou sal do mesmo
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SELDAR PHARMA INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time